Bristol-Myers Squibb Announces Dividend

NEW YORK--(BUSINESS WIRE)-- The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of 33 cents ($0.33) per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on November 1, 2011, to stockholders of record at the close of business on October 11, 2011.

The Directors also declared a quarterly dividend of 50 cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable December 1, 2011, to stockholders of record at the close of business on November 4, 2011.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Research  Diabetes  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.